These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 12601450)

  • 1. [Hodgkin's lymphoma in nuclear medicine: diagnostic and therapeutic aspects].
    Staak JO; Dietlein M; Engert A; Weihrauch MR; Schomäcker K; Fischer T; Eschner W; Borchmann P; Diehl V; Schicha H; Schnell R
    Nuklearmedizin; 2003 Feb; 42(1):19-24. PubMed ID: 12601450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography.
    Bodet-Milin C; Kraeber-Bodéré F; Dupas B; Morschhauser F; Gastinne T; Le Gouill S; Campion L; Harousseau JL; Wegener WA; Goldenberg DM; Huglo D
    Haematologica; 2008 Mar; 93(3):390-7. PubMed ID: 18268287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease.
    Kostakoglu L; Coleman M; Leonard JP; Kuji I; Zoe H; Goldsmith SJ
    J Nucl Med; 2002 Aug; 43(8):1018-27. PubMed ID: 12163626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management.
    Pelosi E; Penna D; Deandreis D; Chiappella A; Skanjeti A; Vitolo U; Bisi G
    Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):9-16. PubMed ID: 18235420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of treatment response in patients with lymphoma using [18F]FDG-PET: differences between non-Hodgkin's lymphoma and Hodgkin's disease.
    Spaepen K; Mortelmans L
    Q J Nucl Med; 2001 Sep; 45(3):269-73. PubMed ID: 11788819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is [(18)F]fluorodeoxyglucose positron emission tomography the ultimate tool for response and prognosis assessment?
    Brepoels L; Stroobants S
    Hematol Oncol Clin North Am; 2007 Oct; 21(5):855-69. PubMed ID: 17908624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 18FDG-positron emission tomography in post treatment evaluation of residual mass in Hodgkin's lymphoma: long-term results.
    Rigacci L; Castagnoli A; Dini C; Carpaneto A; Matteini M; Alterini R; Carrai V; Nassi L; Bernardi F; Pieroni C; Bosi A
    Oncol Rep; 2005 Nov; 14(5):1209-14. PubMed ID: 16211287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic value of 18F-FDG PET-CT in the management of Hodgkin's lymphoma: preliminary results of a prospective study.
    Paolini R; Rampin L; Rodella E; Ramazzina E; Banti E; Al-Nahhas A; Rubello D
    Nucl Med Rev Cent East Eur; 2007; 10(2):87-90. PubMed ID: 18228212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation.
    Guay C; Lépine M; Verreault J; Bénard F
    J Nucl Med; 2003 Aug; 44(8):1225-31. PubMed ID: 12902411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical value of FDG PET using coincident gamma cameras in staging and restaging of malignant lymphoma--compared with convenitonal diagnostic methods].
    Pichler R; Maschek W; Hatzl-Griesenhofer M; Huber H; Wimmer G; Wahl G; Fridrik M
    Nuklearmedizin; 2000 Sep; 39(6):166-73. PubMed ID: 11057408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed?
    Schaefer NG; Taverna C; Strobel K; Wastl C; Kurrer M; Hany TF
    Radiology; 2007 Jul; 244(1):257-62. PubMed ID: 17581905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of positron emission tomography using fluorine-18-fluorodeoxyglucose in patients treated for malignant lymphoma.
    Cremerius U; Fabry U; Neuerburg J; Zimny M; Bares R; Osieka R; Büll U
    Nuklearmedizin; 2001 Feb; 40(1):23-30. PubMed ID: 11373935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Staging, response to therapy, and restaging of lymphomas with 18F-FDG PET.
    Altamirano J; Esparza JR; de la Garza Salazar J; Calvo PS; Vera SR; Chalapud Revelo JR; Estrada G
    Arch Med Res; 2008 Jan; 39(1):69-77. PubMed ID: 18067998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The development of quality assurance programs for radiotherapy within the German Hodgkin Study Group (GHSG). Introduction, continuing work, and results of the radiotherapy reference panel.
    Müller RP; Eich HT
    Strahlenther Onkol; 2005 Sep; 181(9):557-66. PubMed ID: 16170482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Current status of nuclear medicine. Clinical application of FDG-PET for cancer diagnosis. Malignant lymphoma].
    Higuchi T
    Nihon Igaku Hoshasen Gakkai Zasshi; 2002 May; 62(6):278-83. PubMed ID: 12073634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease.
    Kostakoglu L; Goldsmith SJ; Leonard JP; Christos P; Furman RR; Atasever T; Chandramouly A; Verma S; Kothari P; Coleman M
    Cancer; 2006 Dec; 107(11):2678-87. PubMed ID: 17063502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of FDG positron emission tomography imaging on the management of lymphomas.
    Shah N; Hoskin P; McMillan A; Gibson P; Lowe J; wong WL
    Br J Radiol; 2000 May; 73(869):482-7. PubMed ID: 10884743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of fluorodeoxyglucose-PET imaging in the management of patients with Hodgkin's and non-Hodgkin's lymphomas.
    Kumar R; Maillard I; Schuster SJ; Alavi A
    Radiol Clin North Am; 2004 Nov; 42(6):1083-100. PubMed ID: 15488559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic response of non-Hodgkin's lymphoma to 131I-anti-B1 radioimmunotherapy: evaluation with FDG PET.
    Torizuka T; Zasadny KR; Kison PV; Rommelfanger SG; Kaminski MS; Wahl RL
    J Nucl Med; 2000 Jun; 41(6):999-1005. PubMed ID: 10855624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma.
    Shen YY; Kao A; Yen RF
    Oncol Rep; 2002; 9(2):321-5. PubMed ID: 11836600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.